Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Johnson & Johnson : to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference

10/19/2020 | 09:20am EST

New Brunswick, NJ -- Johnson & Johnson (NYSE: JNJ) will participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on Wednesday, November 11th. Joaquin Duato, Vice Chairman of the Executive Committee and Thibaut Mongon, Executive Vice President, Worldwide Chairman Consumer Health will represent the Company in a session scheduled at 11:45 a.m. (Eastern Time).

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

A webcast replay will be available approximately 48-hours after the live webcast.

Press Contacts:

Cristal Downing

(732) 524-3283

(908) 616-6250 (M)

Investor Contacts:

Jennifer McIntyre

(732) 524-3922

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about JOHNSON & JOHNSON
12/01JOHNSON & JOHNSON : European Commission Approves Janssen's TREMFYA®▼ (guse..
PU
12/01JOHNSON & JOHNSON : New Survey Finds Critical Need for Education on Cataracts an..
PR
11/27Covid-19 Vaccine Studies May Suffer as Volunteers Consider Dropping Out
DJ
11/26JOHNSON & JOHNSON : Janssen Pharmaceutical Companies - European Commission Appro..
AQ
11/25JOHNSON & JOHNSON : Pfizer, and Merck Lost $3.5B in Combined YTD Revenue
AQ
11/23JOHNSON & JOHNSON : Janssen Submits Paliperidone Palmitate 6-Month (PP6M) Supple..
PU
11/23JOHNSON & JOHNSON : Initiates Second Global Phase 3 Clinical Trial of its Jansse..
PU
11/23JOHNSON & JOHNSON : New XARELTO® (rivaroxaban) Peripheral Artery Disease (PAD) D..
PU
11/23JOHNSON & JOHNSON : Janssen Submits Application to U.S. FDA for New Indication t..
PU
11/23JOHNSON & JOHNSON : Late-Breaking 12-Month Data of Investigational RPGR Gene The..
PU
More news
Financials (USD)
Sales 2020 81 771 M - -
Net income 2020 15 967 M - -
Net Debt 2020 6 543 M - -
P/E ratio 2020 24,3x
Yield 2020 2,69%
Capitalization 388 B 388 B -
EV / Sales 2020 4,83x
EV / Sales 2021 4,37x
Nbr of Employees 132 200
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | MarketScreener
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 164,73 $
Last Close Price 147,45 $
Spread / Highest target 22,1%
Spread / Average Target 11,7%
Spread / Lowest Target -5,73%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.08%388 168
ROCHE HOLDING AG-4.76%282 467
PFIZER, INC.3.21%212 942
NOVARTIS AG-10.48%206 479
MERCK & CO., INC.-11.61%203 389
ABBVIE INC.18.12%184 633